# IFNA1

## Overview
The IFNA1 gene encodes the protein interferon alpha 1, a member of the type I interferon family, which plays a pivotal role in the immune response. As a cytokine, interferon alpha 1 is involved in antiviral defense mechanisms, primarily by modulating immune system activities such as activating immune cells and enhancing antigen presentation. This protein is characterized by its ability to bind to the interferon alpha/beta receptor complex, initiating signaling pathways that lead to the transcription of interferon-stimulated genes. These genes are crucial for antiviral defense and immune regulation. The IFNA1 gene's expression and function are significant in the context of autoimmune diseases, where dysregulation can contribute to conditions such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, IFNA1 is involved in responses to viral infections and cancer, highlighting its dual role in protective immunity and potential pathological processes (Wittling2021Shared; Barrat2019Interferon; Ramaswamy2021The).

## Structure
The IFNA1 protein, a member of the type I interferon family, is characterized by its specific amino acid sequence, which forms the primary structure. The secondary structure of IFNA1 includes alpha helices, which are typical of type I interferons. The tertiary structure is a compact, globular form stabilized by disulfide bonds, which are crucial for maintaining its stability and function (Wittling2021Shared). 

The quaternary structure of IFNA1 may involve the formation of homodimers or heterodimers, although specific details on this aspect are not extensively covered in the available literature. Post-translational modifications, such as glycosylation, are common in type I interferons and can influence the stability and activity of the protein. However, specific glycosylation sites for IFNA1 are not detailed in the provided context (Wittling2021Shared).

The IFNA1 subtype is noted for its unique receptor binding characteristics, particularly its low affinity for the IFNAR2 receptor, attributed to specific amino acid substitutions that affect its binding interactions (Wittling2021Shared). These structural features contribute to its distinct functional properties within the interferon family.

## Function
The IFNA1 gene encodes a type I interferon protein, interferon alpha 1, which plays a crucial role in the immune response. In healthy human cells, IFNA1 is involved in antiviral defense mechanisms by modulating the immune system. It achieves this by activating immune cells and enhancing antigen presentation, which is essential for the body's ability to recognize and respond to viral infections (Barrat2019Interferon; Tanaka2012Expression).

Interferon alpha proteins, including those encoded by IFNA1, are cytokines that exert their effects primarily in the cytoplasm and extracellular space. They influence various cellular processes such as cell proliferation and apoptosis, contributing to the regulation of immune responses and maintaining tissue integrity under homeostatic conditions (Barrat2019Interferon; Tanaka2012Expression).

The molecular activity of IFNA1 involves binding to specific receptors on the cell surface, which activates signaling pathways involving protein tyrosine kinases JAK1 and TYK2. This leads to the phosphorylation of STAT1 and STAT2, forming the ISGF3 complex. This complex then binds to DNA elements known as interferon-sensitive response elements (ISREs), activating interferon-stimulated genes (ISGs) that include antiviral proteins and transcription factors (Barrat2019Interferon).

## Clinical Significance
Alterations in the expression of the IFNA1 gene, which encodes interferon alpha 1, are implicated in several autoimmune diseases. In systemic lupus erythematosus (SLE), dysregulated activation of the type I interferon pathway, including IFNA1, contributes to disease development by promoting autoantibody production and inflammation (Ramaswamy2021The). Elevated levels of IFNA1 are also observed in other autoimmune conditions such as rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome, where they are associated with disease severity and activity (López2016The; DelgadoVega2010Genetic).

Genetic polymorphisms in interferon pathway genes, including IFNA1, have been identified as predisposing factors for SLE, contributing to immune dysregulation (Ramaswamy2021The). The overexpression of IFNA1 and related genes forms an "interferon signature" that is prevalent in SLE and other autoimmune diseases, indicating a common pathogenic mechanism (Barrat2019Interferon).

In addition to autoimmune diseases, IFNA1 expression is relevant in viral infections and cancer. While it plays a protective role in limiting viral replication, excessive IFNA1 activity can inhibit appropriate antibody responses, potentially affecting the outcome of infections and cancer therapies (Sugrue2021Type).

## Interactions
IFNA1 interacts with the interferon alpha/beta receptor (IFNAR) complex, which consists of IFNAR1 and IFNAR2 subunits. IFNA1 has a notably low affinity for the IFNAR2 receptor, at least 100-fold lower than most other IFNa subtypes, due to specific amino acid substitutions such as F27S and R22S. Despite this, it binds with relatively high affinity to IFNAR1 (Wittling2021Shared). This interaction initiates the JAK-STAT signaling pathway, leading to the transcription of interferon-stimulated genes (Wittling2021Shared).

The regulation of IFNA1 expression involves interactions with transcription factors IRF-3 and IRF-7. These factors bind to specific promoter regions of the IFNA1 gene, with IRF-7 binding to PRDI-like sites and IRF-3 binding to PRDIII regions. This binding is crucial for the activation of IFNA1, IFNA2, and IFNA14 promoters (Lin2000Selective).

At the RNA level, IFNA1 mRNA stability is influenced by interactions with natural antisense RNA (AS) and microRNA-1270. The IFNA1 AS can prevent miRNA-induced destabilization of IFNA1 mRNA by masking the miR-1270 binding site, thus increasing mRNA stability (Kimura2015Interferonalpha).


## References


[1. (López2016The) Consuelo M. López de Padilla and Timothy B. Niewold. The type i interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases. Gene, 576(1):14–21, January 2016. URL: http://dx.doi.org/10.1016/j.gene.2015.09.058, doi:10.1016/j.gene.2015.09.058. This article has 92 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2015.09.058)

[2. (Ramaswamy2021The) Madhu Ramaswamy, Raj Tummala, Katie Streicher, Andre Nogueira da Costa, and Philip Z. Brohawn. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. International Journal of Molecular Sciences, 22(20):11286, October 2021. URL: http://dx.doi.org/10.3390/ijms222011286, doi:10.3390/ijms222011286. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222011286)

[3. (Sugrue2021Type) Jamie A. Sugrue, Nollaig M. Bourke, and Cliona O’Farrelly. Type i interferon and the spectrum of susceptibility to viral infection and autoimmune disease: a shared genomic signature. Frontiers in Immunology, November 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.757249, doi:10.3389/fimmu.2021.757249. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.757249)

[4. (Kimura2015Interferonalpha) Tominori Kimura, Shiwen Jiang, Noriyuki Yoshida, Ryou Sakamoto, and Mikio Nishizawa. Interferon-alpha competing endogenous rna network antagonizes microrna-1270. Cellular and Molecular Life Sciences, 72(14):2749–2761, March 2015. URL: http://dx.doi.org/10.1007/s00018-015-1875-5, doi:10.1007/s00018-015-1875-5. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-015-1875-5)

[5. (DelgadoVega2010Genetic) Angélica M Delgado-Vega, Marta E Alarcón-Riquelme, and Sergey V Kozyrev. Genetic associations in type i interferon related pathways with autoimmunity. Arthritis Research &amp; Therapy, 12(Suppl 1):S2, 2010. URL: http://dx.doi.org/10.1186/ar2883, doi:10.1186/ar2883. This article has 29 citations.](https://doi.org/10.1186/ar2883)

[6. (Wittling2021Shared) Megen C. Wittling, Shannon R. Cahalan, Eric A. Levenson, and Ronald L. Rabin. Shared and unique features of human interferon-beta and interferon-alpha subtypes. Frontiers in Immunology, January 2021. URL: http://dx.doi.org/10.3389/fimmu.2020.605673, doi:10.3389/fimmu.2020.605673. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2020.605673)

[7. (Barrat2019Interferon) Franck J. Barrat, Mary K. Crow, and Lionel B. Ivashkiv. Interferon target-gene expression and epigenomic signatures in health and disease. Nature Immunology, 20(12):1574–1583, November 2019. URL: http://dx.doi.org/10.1038/s41590-019-0466-2, doi:10.1038/s41590-019-0466-2. This article has 337 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41590-019-0466-2)

[8. (Lin2000Selective) Rongtuan Lin, Pierre Génin, Yaël Mamane, and John Hiscott. Selective dna binding and association with the creb binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Molecular and Cellular Biology, 20(17):6342–6353, September 2000. URL: http://dx.doi.org/10.1128/mcb.20.17.6342-6353.2000, doi:10.1128/mcb.20.17.6342-6353.2000. This article has 235 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.17.6342-6353.2000)

[9. (Tanaka2012Expression) Marcia H. Tanaka, Elisa M.A. Giro, Lícia B. Cavalcante, Juliana R. Pires, Luciano H. Apponi, Sandro R. Valentini, Denise M.P. Spolidório, Marisa V. Capela, Carlos Rossa Jr., and Raquel M. Scarel-Caminaga. Expression of interferon-γ, interferon-α and related genes in individuals with down syndrome and periodontitis. Cytokine, 60(3):875–881, December 2012. URL: http://dx.doi.org/10.1016/j.cyto.2012.08.020, doi:10.1016/j.cyto.2012.08.020. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cyto.2012.08.020)